{"company":{"id":3783032,"name":"2024 Epigenic Therapeutics, Inc.","domain":"epigenictx.com","url":"https://alion.io/company/world-42"},"section":"news","answer":"2024 Epigenic Therapeutics, Inc.: 21 headlines on record, 0 headlines in the last 90 days. Its story counts 1 milestone.","figures":[{"label":"Headlines","value":"21"},{"label":"In 90 days","value":"0"},{"label":"Milestones","value":"1"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":21},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":1}],"news":[{"date":"2026-08-17","kind":"Blog","title":"首页","url":"https://cn.epigenictx.com/index"},{"date":"2026-08-17","kind":"Blog","title":"联系我们","url":"https://cn.epigenictx.com/contact-us"},{"date":"2026-08-17","kind":"Blog","title":"临床类","url":"https://cn.epigenictx.com/career-development/invite/clinic"},{"date":"2026-08-17","kind":"Blog","title":"职位招聘","url":"https://cn.epigenictx.com/career-development/invite/all"},{"date":"2026-08-17","kind":"Blog","title":"职业发展","url":"https://cn.epigenictx.com/career-development/careers"},{"date":"2026-08-17","kind":"Blog","title":"出版物","url":"https://cn.epigenictx.com/media/publications"},{"date":"2026-08-17","kind":"Blog","title":"新闻","url":"https://cn.epigenictx.com/media/public-releases"},{"date":"2026-08-17","kind":"Blog","title":"新闻活动","url":"https://cn.epigenictx.com/media/all"},{"date":"2026-08-17","kind":"Blog","title":"研发管线","url":"https://cn.epigenictx.com/innovation/pipeline"},{"date":"2026-08-17","kind":"Blog","title":"研发创新","url":"https://cn.epigenictx.com/innovation/platform"},{"date":"2026-08-17","kind":"Blog","title":"益杰立科","url":"https://cn.epigenictx.com/epigenic/about"},{"date":"2026-03-03","kind":"Blog","title":"益杰立科任命Chloe You博士为首席医学官、Kelly Shi博士为首席财务官助力全球临床开发与资本战略布局","url":"https://cn.epigenictx.com/media/public-releases/30"},{"date":"2026-01-15","kind":"Blog","title":"益杰立科表观遗传疗法EPI-003获NMPA临床试验许可乙肝治疗全球开发进程加速","url":"https://cn.epigenictx.com/media/public-releases/29"},{"date":"2025-10-10","kind":"Blog","title":"益杰立科受邀出席美国纽约2025年Chardan第九届年度基因药物会议","url":"https://cn.epigenictx.com/media/public-releases/27"},{"date":"2025-10-01","kind":"Blog","title":"Nature Biotechnology 发布益杰立科最新研究：新型表观调节器在灵长类中实现高效、长期的降血脂治疗","url":"https://cn.epigenictx.com/media/publications/26"},{"date":"2025-09-08","kind":"Blog","title":"益杰立科宣布完成6000万美元B轮融资加速表观遗传药物临床开发进程","url":"https://cn.epigenictx.com/media/public-releases/25"},{"date":"2024-12-10","kind":"Blog","title":"益杰立科入驻拜耳Co.Lab","url":"https://cn.epigenictx.com/media/public-releases/23"},{"date":"2024-11-20","kind":"Blog","title":"益杰立科EPI-003即将进入临床试验：首款表观调控抑制剂用于治疗慢性乙型肝炎","url":"https://cn.epigenictx.com/media/public-releases/22"},{"date":"2024-10-26","kind":"Blog","title":"益杰立科受邀将在2024年AASLD年会汇报抗乙肝病毒项目的最新研究进展","url":"https://cn.epigenictx.com/media/public-releases/21"},{"date":"2024-09-02","kind":"Blog","title":"益杰立科宣布入选\"2024福布斯亚太区100家最值得关注的企业\"榜单","url":"https://cn.epigenictx.com/media/public-releases/20"},{"date":"2024-05-01","kind":"Blog","title":"益杰立科受邀将在2024年EASL年会展示公司表观基因调控技术用于消除HBV病毒抗原的临床前研究进展","url":"https://cn.epigenictx.com/media/public-releases/13"}],"story":[{"title":"Founded"}],"as_of":"2026-11-17","cite":"2024 Epigenic Therapeutics, Inc., News. Alion, Nov 17, 2026. https://alion.io/company/world-42/news","html_url":"https://alion.io/company/world-42/news","json_url":"https://alion.io/company/world-42/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T23:02:19Z"}}